ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With the AXERA (Device Name) 2 Access System

Inclusion Criteria: * Subject is between 18 and 85 years of age. * Cardiac catheterization procedure is indicated with involving access through a 5 French (F) or 6 French (F) introducer in the femoral artery. * Subject is able to ambulate without assistance prior to the procedure and can be expected to ambulate (20 feet) post-procedure. * Subject or legally authorized representative has signed informed consent. Exclusion Criteria: * Subject is unable to routinely 20 feet without assistance (e.g. requires a walker or wheelchair to mobilize or has paralysis) * Subject has an active systemic or cutaneous infection or inflammation (e.g. (septicemia at the time of the procedure). * Subject undergoing emergent or urgent cardiac catheterization for acute myocardial infarction. * Extensive calcification of the femoral artery as see on fluoroscopy. * Subject has systemic hypertension unresponsive to treatment (\>180mm Hg systolic and \>110mm Hg diastolic). * Subject has received thrombolytic therapy within the 72 hours prior to catheterization. * Subject has known bleeding disorder,such as Factor 5 deficiency, Idiopathic thrombocytopenic purpura (ITP), thrombasthenia, Von Willebrand's disease. * Is on warfarin with an International Ratio (INR)\>1.5. * Platelet count is \< 100,000. * Anemia (Hemoglobin \<10 g/dl or Hematocrit\<30%). * Subject has compromised femoral artery access site. * Subject procedure requires an introducer sheath size of \> 6 French (F). * Subject has had prior vascular surgery or vascular grafts at the femoral artery access site. * Subject presents with hemodynamic instability or is in need of emergent surgery. * Subject has received femoral artery closure on the target access vessel with a collagen/PEG closure device within 90 days. * Subject has a pre-existing severe non-cardiac systemic disease or illness that results in an expected life expectancy of \< 1 year. * Subject is participating in an investigational drug or another device research study that interferes with the current research study endpoints. * Pregnant or lactating subjects.